Trends in the incidence of serous fallopian tube, ovarian, and peritoneal cancer in the US

Gynecologic Oncology

Volumn 149, Issue 2, 2018, Pages 318-323

  Liao, Cheng I ^a,b,c,d   Chow, Stephanie ^e   Chen, Lee may ^f   Kapp, Daniel S ^g   Mann, Amandeep ^h   Chan, John K ⁱ  

^a KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^e KAISER PERMANENTE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h PALO ALTO MEDICAL FOUNDATION RESEARCH INSTITUTE   (United States)

ⁱ PALO ALTO MEDICAL FOUNDATION   (United States)

Author keywords

Fallopian tube cancer; Incidence

Indexed keywords

AGE; AGED; ARTICLE; ASIAN; BLACK PERSON; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER INCIDENCE; CANCER STAGING; CANCER STATISTICS; CAUCASIAN; ETHNICITY; FEMALE; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PACIFIC ISLANDER; PERITONEUM CANCER; POPULATION RESEARCH; PRIORITY JOURNAL; RACE DIFFERENCE; SEROUS FALLOPIAN TUBE CANCER; SEROUS OVARIAN CANCER; SEROUS PERITONEAL CANCER; TREND STUDY; UNITED STATES; UTERINE TUBE CARCINOMA; CANCER REGISTRY; CYSTADENOCARCINOMA; INCIDENCE; MIDDLE AGED; NEOPLASM; OVARY TUMOR; PATHOLOGY; PERITONEUM TUMOR; UTERINE TUBE TUMOR;

AGE FACTORS; AGED; CYSTADENOCARCINOMA, SEROUS; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; INCIDENCE; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; SEER PROGRAM; UNITED STATES;

EID: 85042732775     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2018.01.030     Document Type: Article

References (40)

1. Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2017. CA Cancer J. Clin. 67 (2017), 7–30.
2. Heintz, A.P., Odicino, F., Maisonneuve, P., Beller, U., Benedet, J.L., Creasman, W.T., et al. Carcinoma of the ovary. J. Epidemiol. Biostat. 6 (2001), 107–138.
3. Moss, E.L., Evans, T., Pearmain, P., Askew, S., Singh, K., Chan, K.K., et al. Should all cases of high-grade serous ovarian, tubal, and primary peritoneal carcinomas be reclassified as tubo-ovarian serous carcinoma?. Int. J. Gynecol. Cancer 25 (2015), 1201–1207.
4. Crum, C.P., Drapkin, R., Miron, A., Ince, T.A., Muto, M., Kindelberger, D.W., et al. The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr. Opin. Obstet. Gynecol. 19 (2007), 3–9.
5. Lee, Y., Medeiros, F., Kindelberger, D., Callahan, M.J., Muto, M.G., Crum, C.P., Advances in the recognition of tubal intraepithelial carcinoma: applications to cancer screening and the pathogenesis of ovarian cancer. Adv. Anat. Pathol. 13 (2006), 1–7.
6. Medeiros, F., Muto, M.G., Lee, Y., Elvin, J.A., Callahan, M.J., Feltmate, C., et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am. J. Surg. Pathol. 30 (2006), 230–236.
7. Singh, N., McCluggage, W.G., Gilks, C.B., High-grade serous carcinoma of tubo-ovarian origin: recent developments. Histopathology 71 (2017), 339–356.
8. Prat, J., Oncology FCoG, Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int. J. Gynaecol. Obstet. 124 (2014), 1–5.
9. Gottschau, M., Mellemkjaer, L., Hannibal, C.G., Kjaer, S.K., Ovarian and tubal cancer in Denmark: an update on incidence and survival. Acta Obstet. Gynecol. Scand. 95 (2016), 1181–1189.
10. Rottmann, M., Burges, A., Mahner, S., Anthuber, C., Beck, T., Grab, D., et al. Cancer of the ovary, fallopian tube, and peritoneum: a population-based comparison of the prognostic factors and outcomes. J. Cancer Res. Clin. Oncol. 143:9 (2017), 1833–1844.
11. Usach, I., Blansit, K., Chen, L.M., Ueda, S., Brooks, R., Kapp, D.S., et al. Survival differences in women with serous tubal, ovarian, peritoneal, and uterine carcinomas. Am. J. Obstet. Gynecol. 212:188 (2015), e1–e6.
12. Goodman, M.T., Shvetsov, Y.B., Incidence of ovarian, peritoneal, and fallopian tube carcinomas in the United States, 1995–2004. Cancer Epidemiol. Biomark. Prev. 18 (2009), 132–139.
13. 2001–2014 Database, National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database: NPCR and SEER Incidence – USCS 2001–2014 Public Use Research Database, United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Released August 2017, based on the November 2016 submission. Accessed at www.cdc.gov/cancer/npcr/public-use.
14. United States Census Bureau, https://www2.census.gov/geo/pdfs/maps-data/maps/reference/us_regdiv.pdf.
15. Clegg, L.X., Hankey, B.F., Tiwari, R., Feuer, E.J., Edwards, B.K., Estimating average annual per cent change in trend analysis. Stat. Med. 28 (2009), 3670–3682.
16. Surveillance Research Program, National Cancer Institute SEER*Stat software (www.seer.cancer.gov/seerstat) version 8.3.4. SEER*Stat Database: NPCR and SEER Incidence - Public Use Data - 2001–2014 - jbk 062817.
17. Kim, H.J., Fay, M.P., Feuer, E.J., Midthune, D.N., Permutation tests for joinpoint regression with applications to cancer rates. Stat. Med. 19 (2000), 335–351.
18. Joinpoint Regression Program, Version 4.5.0.1. 2016, Statistical Research and Applications Branch, National Cancer Institute, Bethesda, MD.
19. McDonald, E., EB H., Epidemiology of Cancer in Texas. Incidence Analyzed by Type, Ethnic Group, and Geographic Location. 1978, Raven Press, New York.
20. Pfeiffer, P., Mogensen, H., Amtrup, F., Honore, E., Primary carcinoma of the fallopian tube. A retrospective study of patients reported to the Danish Cancer Registry in a five-year period. Acta Oncol. 28 (1989), 7–11.
21. Rosenblatt, K.A., Weiss, N.S., Schwartz, S.M., Incidence of malignant fallopian tube tumors. Gynecol. Oncol. 35 (1989), 236–239.
22. Riska, A., Leminen, A., Pukkala, E., Sociodemographic determinants of incidence of primary fallopian tube carcinoma, Finland 1953–97. Int. J. Cancer 104 (2003), 643–645.
23. Clayton, N.L., Jaaback, K.S., Hirschowitz, L., Primary fallopian tube carcinoma — the experience of a UK cancer centre and a review of the literature. J. Obstet. Gynaecol. 25 (2005), 694–702.
24. Diniz, P.M., Carvalho, J.P., Baracat, E.C., Carvalho, F.M., Fallopian tube origin of supposed ovarian high-grade serous carcinomas. Clinics (Sao Paulo) 66 (2011), 73–76.
25. Folkins, A.K., Jarboe, E.A., Saleemuddin, A., Lee, Y., Callahan, M.J., Drapkin, R., et al. A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecol. Oncol. 109 (2008), 168–173.
26. Shaw, P.A., Rouzbahman, M., Pizer, E.S., Pintilie, M., Begley, H., Candidate serous cancer precursors in fallopian tube epithelium of BRCA1/2 mutation carriers. Mod. Pathol. 22 (2009), 1133–1138.
27. Powell, C.B., Chen, L.M., McLennan, J., Crawford, B., Zaloudek, C., Rabban, J.T., et al. Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol. Int. J. Gynecol. Cancer 21 (2011), 846–851.
28. College of American Pathologists, http://www.cap.org/ShowProperty?nodePath=/UCMCon/Contribution%20Folders/WebContent/pdf/fallopiantube-15protocol-3102.pdf.
29. College of American Pathologists, http://www.cap.org/ShowProperty?nodePath=/UCMCon/Contribution%20Folders/WebContent/pdf/cp-ovary-fallopian-17protocol-1000.pdf.
30. McCluggage, W.G., Hirschowitz, L., Gilks, C.B., Wilkinson, N., Singh, N., The fallopian tube origin and primary site assignment in extrauterine high-grade serous carcinoma: findings of a survey of pathologists and clinicians. Int. J. Gynecol. Pathol. 36 (2017), 230–239.
31. Dilley, S.E., Straughn, J.M., Leath, C.A., The evolution of and evidence for opportunistic salpingectomy. Obstet. Gynecol. 130 (2017), 814–824.
32. McAlpine, J.N., Hanley, G.E., Woo, M.M., Tone, A.A., Rozenberg, N., Swenerton, K.D., et al. Opportunistic salpingectomy: uptake, risks, and complications of a regional initiative for ovarian cancer prevention. Am. J. Obstet. Gynecol. 210:471 (2014), e1–e11.
33. Stewart, S.L., Wike, J.M., Foster, S.L., Michaud, F., The incidence of primary fallopian tube cancer in the United States. Gynecol. Oncol. 107 (2007), 392–397.
34. Latzko, W., Linkseitiges tubenkarzinom rechtseitige karzinomatose tuboovarial cyste. Zentralbl. Gynakol., 40, 1916, 599.
35. Nordin, A.J., Primary carcinoma of the fallopian tube: a 20-year literature review. Obstet. Gynecol. Surv. 49 (1994), 349–361.
36. Ou, Y.C., Huang, H.Y., Huang, C.C., Changchien, C.C., Tseng, C.W., Lin, H., Primary fallopian tube carcinoma: clinicopathological analysis of 12 cases. Taiwan J. Obstet. Gynecol. 50 (2011), 141–144.
37. Friedrich, M., Villena-Heinsen, C., Schweizer, J., Holländer, M., Stieber, M., Schmidt, W., Primary tubal carcinoma: a retrospective analysis of four cases with a literature review. Eur. J. Gynaecol. Oncol. 19 (1998), 138–143.
38. Moore, K.N., Moxley, K.M., Fader, A.N., Axtell, A.E., Rocconi, R.P., Abaid, L.N., et al. Serous fallopian tube carcinoma: a retrospective, multi-institutional case-control comparison to serous adenocarcinoma of the ovary. Gynecol. Oncol. 107 (2007), 398–403.
39. Piver, M.S., Tsukada, Y., Werness, B.A., DiCioccio, R.A., Whittemore, A.S., Ponder, B.A., Comparative study of ovarian cancer histopathology by registry pathologists and referral pathologists: a study by the Gilda Radner Familial Ovarian Cancer Registry. Gynecol. Oncol. 78 (2000), 166–170.
40. Centers for Disease Control and Prevention, https://www.cdc.gov/cancer/npcr/about.htm.